Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144384 · ClinicalTrials.gov registry record · Early Phase 1
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
A Early Phase 1 study of Skin Squamous Cell Carcinoma and Skin Basal Cell Carcinoma, sponsored by Kirsten Johnson.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07144384 is a Early Phase 1 study of Skin Squamous Cell Carcinoma and Skin Basal Cell Carcinoma that is actively recruiting participants, run by Kirsten Johnson. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07144384, a Early Phase 1 study of Skin Squamous Cell Carcinoma and Skin Basal Cell Carcinoma, is actively recruiting participants, sponsored by Kirsten Johnson.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial compares the safety, side effects and the biological or cellular activity of two types of universal donor (UD) natural killer (NK) cells (standard NK cells and transforming growth factor \[TGF\] beta imprinted \[TGF-beta-i\] NK cells), given directly into the tumor (intratumoral) in treating patients with skin (cutaneous) squamous cell carcinoma (SCC) or basal cell carcinoma (BCC). NK cells are a type of white blood cell that can recognize missing or incorrect proteins on tumor cells and then kill these tumor cells. It was recently discovered that infection with human cytomegalovirus (CMV), a common virus, leads to the development of a unique NK cell population. These "adaptive" NK cells have a more potent anti-tumor killing action. The TGF-beta-i NK cells used in this study are created using donors whose blood tests positive for CMV exposure. This may make them more effective at killing tumor cells. Giving UD TGF-beta-i NK cells may be safe, tolerable and/or more effective than standard UD expanded NK cells in treating patients with SCC or BCC.
Conditions Studied
Interventions
- PROCEDURE Biopsy Procedure
- PROCEDURE Surgical Procedure
- BIOLOGICAL Natural Killer Cell Therapy
- BIOLOGICAL Universal Donor Expanded TGF-beta-imprinted NK Cells
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07144384
The ClinicalTrials.gov registry entry for NCT07144384 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kirsten Johnson, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Skin Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Biopsy Procedure is the first listed.
NCT07144384 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07144384 about?
NCT07144384 is a clinical study titled "Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma". This early phase I trial compares the safety, side effects and the biological or cellular activity of two types of universal donor (UD) natural killer (NK) cells (standard NK cells and transforming growth factor \[TGF\] beta imprinted \[TGF-beta-i\] NK cells), given directly into the tumor (intratum...
What is the current status of trial NCT07144384?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2025-10-16. Estimated completion is 2026-12-31.
What conditions does trial NCT07144384 study?
This clinical trial studies the following conditions: Skin Squamous Cell Carcinoma, Skin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma.
What interventions are being tested in trial NCT07144384?
The interventions under investigation include: Biopsy Procedure (PROCEDURE), Surgical Procedure (PROCEDURE), Natural Killer Cell Therapy (BIOLOGICAL), Universal Donor Expanded TGF-beta-imprinted NK Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07144384?
This trial is sponsored by Kirsten Johnson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07144384 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.